rtPA Infusion Dose Calculator

लाखों नवीनतम Android ऐप्स, गेम्स, संगीत, फ़िल्में, टीवी, पुस्तकें, पत्रिकाएं आदि का आनंद लें. आपके सभी डिवाइस पर, किसी भी समय, कहीं भी.

Recombinant tissue plasminogen activator (rt-PA) was approved by the FDA in 1996 for the treatment of acute ischemic stroke. Despite its proven efficacy, however, rt-PA therapy has not been widely used among ischemic stroke patients. Studies have estimated that only 1.8% to 3.0% of all ischemic stroke patients in the United States are treated with rt-PA; the upper end of that range was not achieved until FY 2007. There are many reasons why rt-PA is not administered to more stroke patients, the most important of which is prehospital delays in presentation. Within the US population, only 8% of ischemic stroke patients present to an emergency department eligible for rt-PA. In addition, several important systems issues regarding the hospital of presentation affect whether a patient receives rt-PA, such as protocols for acute stroke patient triaging, stroke education for local EMS and ED staff, and 24-hour CT availability.